Treatment-Related Toxicity in Advanced Medullary Thyroid Cancer
0 Views
administrator
07/06/23
Not all patients with advanced medullary thyroid cancer are candidates for vandetanib and cabozantinib, due to treatment-related toxicity. As a result, in this segment, the panelists describe which patients should receive aggressive treatment.
For more from the discussion, visit http://www.onclive.com/peer-exchange/managing-mtc
-
Category
Show more
Facebook Comments
No comments found